Overview

* Janux reports Q2 net loss of $33.9 mln, up from $6.0 mln last year

* Cash and investments at $996.0 mln, down from $1.03 bln at end of 2024

* $10 mln milestone payment from Merck for first patient dosed in collaboration

Outlook

* Janux expects updates on JANX007 and JANX008 in H2 2025

* Company continues enrollment for JANX007 and JANX008 trials

* Company anticipates data presentations in H2 2025

Result Drivers

* CLINICAL MILESTONE - $10 mln payment from Merck triggered by first patient dosed in collaboration program

* PIPELINE PROGRESS - Ongoing enrollment for JANX007 and JANX008 in Phase 1 trials, with updates expected in H2 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$33.86

Income mln

Q2 Basic -$0.55

EPS

Q2 $45.12

Operatin mln

g

Expenses

Q2 -$45.12

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Janux Therapeutics Inc ( JANX ) is $76.00, about 68.2% above its August 6 closing price of $24.18

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)